Broken Promises — How Medicare Part D Has Failed to Deliver Savings to Older Adults

2020 ◽  
Vol 383 (24) ◽  
pp. 2299-2301
Author(s):  
Stacie B. Dusetzina ◽  
Benyam Muluneh ◽  
Nancy L. Keating ◽  
Haiden A. Huskamp
2007 ◽  
Author(s):  
Betty E. Tanius ◽  
Stacey Wood ◽  
Yaniv Hanoch ◽  
Thomas Rice ◽  
Martina Ly ◽  
...  

2009 ◽  
Vol 49 (6) ◽  
pp. 828-838 ◽  
Author(s):  
K. A. Skarupski ◽  
C. F. Mendes de Leon ◽  
L. L. Barnes ◽  
D. A. Evans

2011 ◽  
Vol 19 (12) ◽  
pp. 989-997 ◽  
Author(s):  
Julie M. Donohue ◽  
Yuting Zhang ◽  
Subashan Perera ◽  
Judith R. Lave ◽  
Joseph T. Hanlon ◽  
...  

Medical Care ◽  
2010 ◽  
Vol 48 (5) ◽  
pp. 409-417 ◽  
Author(s):  
Yuting Zhang ◽  
Judith R. Lave ◽  
Julie M. Donohue ◽  
Michael A. Fischer ◽  
Michael E. Chernew ◽  
...  

Diabetes Care ◽  
2016 ◽  
Vol 40 (4) ◽  
pp. 502-508 ◽  
Author(s):  
Yoon Jeong Choi ◽  
Haomiao Jia ◽  
Tal Gross ◽  
Katie Weinger ◽  
Patricia W. Stone ◽  
...  

BMJ Open ◽  
2021 ◽  
Vol 11 (12) ◽  
pp. e053717
Author(s):  
Minghui Li ◽  
Jing Yuan ◽  
Chelsea Dezfuli ◽  
Z Kevin Lu

ObjectiveBenzodiazepines were excluded from Medicare Part D coverage since its introduction in 2006. Part D expanded coverage for benzodiazepines in 2013. The objective was to examine the impact of Medicare Part D coverage expansion on the utilisation and financial burden of benzodiazepines in older adults.DesignInterrupted time series with a control group.SettingNationally representative sample.Participants53 150 468 users of benzodiazepines and 21 749 749 users of non-benzodiazepines (an alternative therapy) from the Medicare Current Beneficiary Survey between the pre-expansion (2006–2012) and post-expansion (2013–2017) periods.InterventionMedicare Part D coverage expansion on benzodiazepines.Primary and secondary outcome measuresAnnual rate of benzodiazepines and non-benzodiazepines, average number of benzodiazepines and non-benzodiazepines and average cost of benzodiazepines and non-benzodiazepines.ResultsAfter Medicare Part D coverage expansion, the level of the annual rate of benzodiazepines increased by 8.20% (95% CI: 6.07% to 10.32%) and the trend decreased by 1.03% each year (95% CI: −1.77% to −0.29%). The trend of the annual rate of non-benzodiazepines decreased by 0.72% each year (95% CI: −1.11% to −0.33%). For the average number of benzodiazepines, the level increased by 0.67 (95% CI: 0.52 to 0.82) and the trend decreased by 0.10 each year (95% CI: −0.15 to –0.05). For the average number of non-benzodiazepines, the level decreased by 0.11 (95% CI: −0.21 to –0.01) and the trend decreased by 0.04 each year (95% CI: −0.08 to –0.01). No significant level and trend changes were identified for the average cost of benzodiazepines and non-benzodiazepines.ConclusionsAfter Medicare Part D coverage expansion, there was a sudden increase in the utilisation of benzodiazepines and a decreasing trend in the long-term. The increase in the utilisation of benzodiazepines did not add a financial burden to older adults. As an alternative therapy, the utilisation of non-benzodiazepines decreased following the coverage expansion.


2016 ◽  
Vol 48 (1) ◽  
pp. 42-56 ◽  
Author(s):  
Cheng-Chia Chen ◽  
Hsien-Chang Lin ◽  
Dong-Chul Seo

This study examined the effect of Medicare (Part D) implementation on health outcomes among U.S. older adults. Study participants were initially extracted from the 2004–2008 Health and Retirement Study (HRS). Data from respondents who further participated in the HRS 2005–2007 Prescription Drug Study were analyzed (N = 746). This was a retrospective pre-post design with a treatment and a control group. The difference-in-differences approach with panel ordered logistic regressions was used to examine the Part D effect on three patient health outcomes before and after the implementation, controlling for patient sociodemographic characteristics. People with continuous Part D enrollment from 2006–2008 were less likely to have a worse self-rated health than those who were not enrolled in Part D (odds ratio [OR] = 0.48; p < .05). A higher Charlson Comorbidity Index score was associated with a higher likelihood of having worse self-rated overall health, worse mental health, and worse activities of daily living impairment (ORs = 1.12, 1.17, and 1.36, respectively; all ps < .001). The Part D implementation appears to have a positive effect on older adults’ overall health outcomes. A decrease in out-of-pocket cost for health care may encourage older adults to utilize more needed medications, which in turn helped maintain better health.


Author(s):  
Adrienne H. Sabety ◽  
Tisamarie B. Sherry ◽  
Nicole Maestas

2021 ◽  
Vol 5 (Supplement_1) ◽  
pp. 608-608
Author(s):  
Jennifer Kirk ◽  
Sean Fleming ◽  
Denise Orwig

Abstract As the United States’ population increasingly consists of older adults aged 65+, an increase is expected in the prevalence of osteoporosis and the number of osteoporotic fractures. Bone-active medications (BAM) delay osteoporosis progression and prevent fragility fractures, but historically low treatment persistence rates and drug utilization for BAM exist among at-risk older adults. This research assessed for differences in the BAM utilization rates over five-years in Medicare Part D by provider type: geriatric specialists (GERO), generalists, specialists, nurse practitioners (NP), and physicians’ assistants (PA). This longitudinal retrospective analysis included providers with at least one BAM prescription among beneficiaries aged 65+. An analysis of response profiles was used to model the mean BAM utilization rates overall and by provider group. Of the 50,249 providers included in this analysis, 88.15% were generalists, 5.76% specialists, 1.48% GERO, 2.73% NP, and 1.87% PA. From 2013-2017, the prevalence of BAM utilization was 6%. Over the five years, BAM utilization rates did not change significantly, but provider-specific rates were significantly different (F=12.53, p&lt;.001). Provider-specific utilization rates were inconsistent with the highest utilization rates and most considerable variation observed among specialists (14.95%). PAs and NPs’ BAM utilization rates were stable at around 9.02% and 9.20%, but GERO and generalists exhibited the lowest utilization rates, 4.86% and 5.79%, respectively. While specialists had the higher-than-expected utilization rates, the overall and provider-specific BAM utilization rates were low and did not increase over time. Further research is needed to identify how provider-related factors, like geographic region and clinical training, influence underutilization.


Sign in / Sign up

Export Citation Format

Share Document